Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Feb 12;30(3):730–739. doi: 10.1038/s41591-023-02791-w

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2024

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 4 — a–c, OS by specific gene alteration in the overall population (a), patients with left-sided primary tumors (b) and patients with right-sided primary tumors (c). Data plotted are HRs ± 95% CI. A Cox proportional hazard model without stratification factors was used to calculate HRs for group comparisons and P values for the interaction between negative hyperselection status and treatment group. Statistical tests were two-sided without adjustment for multiple comparisons. ^aNegative hyperselected patients were WT for all of the following: RAS, BRAF V600E, HER2 amp., MET amp., EGFR ECD, PTEN and ALK/RET/NTRK1 fusion. ^bGene-altered patients had at least one of the following alterations: RAS, BRAF V600E, HER2 amp., MET amp., EGFR ECD, PTEN or ALK/RET/NTRK1 fusion. amp., amplification; NE, not estimable.